tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Is PRLD a Buy, Before Earnings?
PremiumPre-EarningsIs PRLD a Buy, Before Earnings?
27d ago
Prelude Therapeutics Signs Option Agreement with Incyte
Premium
Company Announcements
Prelude Therapeutics Signs Option Agreement with Incyte
1M ago
Why Is Prelude Therapeutics Stock (PRLD) Down 45% Today?
Premium
Market News
Why Is Prelude Therapeutics Stock (PRLD) Down 45% Today?
1M ago
Prelude Therapeutics CMO Jane Huang departs
PremiumThe FlyPrelude Therapeutics CMO Jane Huang departs
1M ago
Prelude Therapeutics announces publication of abstracts for ASH meeting
Premium
The Fly
Prelude Therapeutics announces publication of abstracts for ASH meeting
1M ago
Prelude Therapeutics Advances with PRT7732 in Targeted Cancer Therapy
Premium
Company Announcements
Prelude Therapeutics Advances with PRT7732 in Targeted Cancer Therapy
1M ago
Prelude Therapeutics price target lowered to $3 from $4 at Citizens JMP
PremiumThe FlyPrelude Therapeutics price target lowered to $3 from $4 at Citizens JMP
4M ago
Prelude Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Prelude Therapeutics Reports Q2 2025 Financial Results
4M ago
Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development
Premium
Company Announcements
Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100